Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21706803 | 0.88 | SSTR5 (0.47) | LGALS8SSTR5SSTR1SSTR2SSTR4 | |
| SCHEMBL23914008 | 0.86 | SSTR1 (0.53) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL9745334 | 0.86 | SSTR1 (0.53) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13387386 | 0.86 | SSTR1 (0.53) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL1117738 | 0.83 | PDPK1 (0.44) | LGALS8BCHESLC6A2PDPK1MTOR | |
| SCHEMBL3825138 | 0.82 | LGALS8 (0.50) | LGALS8SSTR5SSTR1SSTR2SSTR4 | |
| SCHEMBL3827358 | 0.82 | LGALS8 (0.50) | LGALS8SSTR5SSTR1SSTR2SSTR4 | |
| SCHEMBL22212491 | 0.81 | LGALS8 (0.49) | LGALS8SSTR5SSTR1SSTR2SSTR4 | |
| SCHEMBL16148039 | 0.79 | PDPK1 (0.45) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL31103781 | 0.79 | PDPK1 (0.45) | SSTR5SSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723754-B2 | 2′,4′-bridged nucleosides for HCV infection | IDENIX PHARMACEUTICALS LLC (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723754-B2 | 2′,4′-bridged nucleosides for HCV infection | SLC29A1, SLC28A1, SLC29A2 | LGALS8 3560/4885SSTR5 4359/4885SSTR1 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.